{"protocolSection":{"identificationModule":{"nctId":"NCT01674647","orgStudyIdInfo":{"id":"15693"},"secondaryIdInfos":[{"id":"2011-002234-39","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","officialTitle":"A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","acronym":"X-VERT"},"statusModule":{"statusVerifiedDate":"2015-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-10"},"primaryCompletionDateStruct":{"date":"2014-01","type":"ACTUAL"},"completionDateStruct":{"date":"2014-01","type":"ACTUAL"},"studyFirstSubmitDate":"2012-08-27","studyFirstSubmitQcDate":"2012-08-27","studyFirstPostDateStruct":{"date":"2012-08-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-01-08","resultsFirstSubmitQcDate":"2015-02-02","resultsFirstPostDateStruct":{"date":"2015-02-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-04-10","lastUpdatePostDateStruct":{"date":"2015-04-30","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm). The study will compare patients assigned randomly (like flipping a coin) to either Rivaroxaban or vitamin K antagonist (VKA). The study will measure common medical outcomes for this type of patient such as bleeding and stroke."},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["rivaroxaban","oral anticoagulant","nonvalvular atrial fibrillation","cardioversion","stroke","transient ischemic attack","thromboembolism","cardiovascular event"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1504,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rivaroxaban (Xarelto, BAY59-7939)","type":"EXPERIMENTAL","description":"A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)"]},{"label":"Vitamin K antagonist (VKA)","type":"ACTIVE_COMPARATOR","description":"A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.","interventionNames":["Drug: Vitamin K antagonist (VKA)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study","armGroupLabels":["Rivaroxaban (Xarelto, BAY59-7939)"]},{"type":"DRUG","name":"Vitamin K antagonist (VKA)","description":"VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards","armGroupLabels":["Vitamin K antagonist (VKA)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death","description":"Stroke, TIA, Non-CNS Embolism, MI and cardiovascular death were adjudicated and confirmed by Clinical Endpoints Committee (CEC). Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. Cardiovascular death included death in subjects with non-valvular atrial fibrillation (AF). Number of subjects with composite events were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Major Bleedings as Per Central Adjudication","description":"Bleeding events were adjudicated and confirmed by CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the International Society on Thrombosis and Hemostasis (ISTH) criteria. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Number of subjects with confirmed adjudicated bleeding events occurring in greater than (\\>)1 total subjects were reported.","timeFrame":"From randomization up to the date of the last dose of study drug + 2 days"}],"secondaryOutcomes":[{"measure":"Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms","description":"Stroke and Non-CNS Embolism were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with composite events were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality","description":"Stroke, TIA, Non- CNS systemic embolism, MI and all-cause mortality were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. All-cause mortality included vascular death and non-vascular death. Number of subjects with composite events were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Strokes","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available). Number of subjects with strokes were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Transient Ischemic Attacks","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Number of subjects with TIA were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Non-central Nervous System Systemic Embolisms","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with non-CNS embolism were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Myocardial Infarctions","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. MI was assessed based onmeither cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. Number of subjects with MI were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Cardiovascular Deaths","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia). Number of subjects with cardiovascular deaths were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With All-cause Mortality","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. All-cause mortality included vascular death and non-vascular death. Number of subjects with all-cause mortality were reported.","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment"},{"measure":"Number of Participants With Composite of Major and Non-major Bleeding Events","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the ISTH criteria. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. Number of subjects with clinically relevant major and non-major bleeding events were reported.","timeFrame":"From randomization up to the date of the last dose of study drug + 2 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women aged \\>= 18 years\n* Hemodynamically stable nonvalvular atrial fibrillation longer than 48 hours or of unknown duration\n* Scheduled for cardioversion (electrical or pharmacological) of nonvalvular atrial fibrillation\n* Women of childbearing potential and men must agree to use adequate contraception when sexually active\n\nExclusion Criteria:\n\n* Severe, disabling stroke (modified Rankin score of 4- 5, inclusive) within 3 months or any stroke within 14 days prior to randomization\n* Transient ischemic attack within 3 days prior to randomization\n* Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to randomization\n* Acute Myocardial infarction (MI) within the last 14 days prior to randomization\n* Cardiac-related criteria: known presence of cardiac thombus or myxoma or valvular atrial fibrillation\n* Active bleeding or high risk for bleeding contraindicating anticoagulant therapy\n* Concomitant medications: indication for anticoagulant therapy other than atrial fibrillation, chronic aspirin therapy \\> 100 mg daily or dual antiplatelet therapy, strong inhibitors of both cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) if used systemically\n* Concomitant conditions: childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; hypersensitivity to investigational treatment or comparator treatment; calculated creatinine clearance (CrCl) \\< 30 mL/minute; hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk; any severe condition that would limit life expectancy to less than 6 months; planned invasive procedure with potential for uncontrolled bleeding; inability to take oral medication; ongoing drug addiction or alcohol abuse\n* Any other contraindication listed in the local labeling for the comparator treatment or experimental treatment\n* Participation in a study with an investigational drug or medical device within 30 days prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bayer Study Director","affiliation":"Bayer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"city":"Scottsdale","state":"Arizona","zip":"85258","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"city":"East Palo Alto","state":"California","zip":"94303","country":"United States","geoPoint":{"lat":37.46883,"lon":-122.14108}},{"city":"El Cajon","state":"California","zip":"92020","country":"United States","geoPoint":{"lat":32.79477,"lon":-116.96253}},{"city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"city":"Sacramento","state":"California","zip":"95819","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"city":"Santa Rosa","state":"California","zip":"95494","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"city":"Torrance","state":"California","zip":"90502-2004","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"city":"Stamford","state":"Connecticut","zip":"06905","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"city":"Wilmington","state":"Delaware","zip":"19803","country":"United States","geoPoint":{"lat":39.74595,"lon":-75.54659}},{"city":"Clearwater","state":"Florida","zip":"33756","country":"United States","geoPoint":{"lat":27.96585,"lon":-82.8001}},{"city":"Daytona Beach","state":"Florida","zip":"32117","country":"United States","geoPoint":{"lat":29.21081,"lon":-81.02283}},{"city":"Deltona","state":"Florida","zip":"32725","country":"United States","geoPoint":{"lat":28.90054,"lon":-81.26367}},{"city":"Ft. Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"city":"Ft. Lauderdale","state":"Florida","zip":"33316","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"city":"Lakeland","state":"Florida","zip":"33805","country":"United States","geoPoint":{"lat":28.03947,"lon":-81.9498}},{"city":"Melbourne","state":"Florida","zip":"32901","country":"United States","geoPoint":{"lat":28.08363,"lon":-80.60811}},{"city":"Miami","state":"Florida","zip":"33135","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"city":"St. Augustine","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":29.89469,"lon":-81.31452}},{"city":"Tallahassee","state":"Florida","zip":"32308","country":"United States","geoPoint":{"lat":30.43826,"lon":-84.28073}},{"city":"Savannah","state":"Georgia","zip":"31419","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"city":"Aurora","state":"Illinois","zip":"60504","country":"United States","geoPoint":{"lat":41.76058,"lon":-88.32007}},{"city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"city":"Rockford","state":"Illinois","zip":"61107","country":"United States","geoPoint":{"lat":42.27113,"lon":-89.094}},{"city":"Annapolis","state":"Maryland","zip":"21401","country":"United States","geoPoint":{"lat":38.97845,"lon":-76.49218}},{"city":"Columbia","state":"Maryland","zip":"21044","country":"United States","geoPoint":{"lat":39.24038,"lon":-76.83942}},{"city":"Rockville","state":"Maryland","zip":"20853","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"city":"Lincoln","state":"Nebraska","zip":"68516","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"city":"North Las Vegas","state":"Nevada","zip":"89086","country":"United States","geoPoint":{"lat":36.19886,"lon":-115.1175}},{"city":"Bridgewater","state":"New Jersey","zip":"08807","country":"United States","geoPoint":{"lat":40.60079,"lon":-74.64815}},{"city":"Manalapan","state":"New Jersey","zip":"07716","country":"United States","geoPoint":{"lat":40.25733,"lon":-74.39571}},{"city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"city":"Buffalo","state":"New York","zip":"14215","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"city":"New York","state":"New York","zip":"10013","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"Troy","state":"New York","zip":"12180","country":"United States","geoPoint":{"lat":42.72841,"lon":-73.69179}},{"city":"Asheville","state":"North Carolina","zip":"28805","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"city":"Cantan","state":"Ohio","zip":"44708","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"city":"Mansfield","state":"Ohio","zip":"44906","country":"United States","geoPoint":{"lat":40.75839,"lon":-82.51545}},{"city":"Toledo","state":"Ohio","zip":"43623","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"city":"Beaver","state":"Pennsylvania","zip":"15009","country":"United States","geoPoint":{"lat":40.69534,"lon":-80.30478}},{"city":"Butler","state":"Pennsylvania","zip":"16001","country":"United States","geoPoint":{"lat":40.86118,"lon":-79.89533}},{"city":"Doylestown","state":"Pennsylvania","zip":"18901","country":"United States","geoPoint":{"lat":40.31011,"lon":-75.12989}},{"city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}},{"city":"Philadelphia","state":"Pennsylvania","zip":"19102","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"city":"Philadelphia","state":"Pennsylvania","zip":"19141","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"city":"Rapid City","state":"South Dakota","zip":"57701","country":"United States","geoPoint":{"lat":44.08054,"lon":-103.23101}},{"city":"Johnson City","state":"Tennessee","zip":"37604","country":"United States","geoPoint":{"lat":36.31344,"lon":-82.35347}},{"city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"city":"Fort Sam Houston","state":"Texas","zip":"78234-6200","country":"United States","geoPoint":{"lat":29.45746,"lon":-98.4472}},{"city":"Tyler","state":"Texas","zip":"75701","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"city":"Layton","state":"Utah","zip":"84041","country":"United States","geoPoint":{"lat":41.06022,"lon":-111.97105}},{"city":"Bellingham","state":"Washington","zip":"98225","country":"United States","geoPoint":{"lat":48.75955,"lon":-122.48822}},{"city":"Burien","state":"Washington","zip":"98166","country":"United States","geoPoint":{"lat":47.47038,"lon":-122.34679}},{"city":"Wausau","state":"Wisconsin","zip":"54401","country":"United States","geoPoint":{"lat":44.95914,"lon":-89.63012}},{"city":"Leuven","state":"Vlaams Brabant","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"city":"Bruxelles - Brussel","zip":"1070","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"city":"Hasselt","zip":"3500","country":"Belgium","geoPoint":{"lat":50.93106,"lon":5.33781}},{"city":"Liege","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"city":"MOL","zip":"2400","country":"Belgium","geoPoint":{"lat":51.19188,"lon":5.11662}},{"city":"Curitiba","state":"Parana","zip":"80730-150","country":"Brazil","geoPoint":{"lat":-25.42778,"lon":-49.27306}},{"city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90610-000","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}},{"city":"Campinas","state":"Sao Paulo","zip":"13010-001","country":"Brazil","geoPoint":{"lat":-22.90556,"lon":-47.06083}},{"city":"Campinas","state":"Sao Paulo","zip":"13060904","country":"Brazil","geoPoint":{"lat":-22.90556,"lon":-47.06083}},{"city":"Sao Paulo","zip":"05403-900","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"city":"Edmonton","state":"Alberta","zip":"T5H 3V9","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"city":"Victoria","state":"British Columbia","zip":"V8R 4R2","country":"Canada","geoPoint":{"lat":48.43294,"lon":-123.3693}},{"city":"Saint John","state":"New Brunswick","zip":"E2L 4L2","country":"Canada","geoPoint":{"lat":45.2727,"lon":-66.06769}},{"city":"St. John's","state":"Newfoundland and Labrador","zip":"A1B 3V6","country":"Canada","geoPoint":{"lat":47.56494,"lon":-52.70931}},{"city":"Hamilton","state":"Ontario","zip":"L8L 2X2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"city":"Toronto","state":"Ontario","zip":"M5B 1W8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"city":"Montreal","state":"Quebec","zip":"H1T 1C8","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"city":"Montreal","state":"Quebec","zip":"H2W 1T8","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"city":"Quebec","zip":"G1V 4G5","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Wuhan","state":"Hubei","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"city":"Changsha","state":"Hunan","zip":"410011","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"city":"Nanchang","state":"Jiangxi","zip":"330006","country":"China","geoPoint":{"lat":28.68396,"lon":115.85306}},{"city":"Changchun","state":"Jilin","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"city":"Xi'an","state":"Shaanxi","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"city":"Urumqi","state":"Xinjiang","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"city":"Beijing","zip":"100029","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"city":"Shanghai","zip":"200080","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shenyang","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"city":"Hellerup","zip":"2900","country":"Denmark","geoPoint":{"lat":55.73204,"lon":12.57093}},{"city":"Herning","zip":"7400","country":"Denmark","geoPoint":{"lat":56.13932,"lon":8.97378}},{"city":"København NV","zip":"2400","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"city":"Viborg","zip":"8800","country":"Denmark","geoPoint":{"lat":56.45319,"lon":9.40201}},{"city":"Helsinki","zip":"FIN-00260","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"city":"Jyväskylä","zip":"40620","country":"Finland","geoPoint":{"lat":62.24147,"lon":25.72088}},{"city":"Lappeenranta","country":"Finland","geoPoint":{"lat":61.05871,"lon":28.18871}},{"city":"Oulu","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"city":"Pori","zip":"28500","country":"Finland","geoPoint":{"lat":61.48333,"lon":21.78333}},{"city":"Rovaniemi","zip":"96101","country":"Finland","geoPoint":{"lat":66.5,"lon":25.71667}},{"city":"Tampere","zip":"FIN-33520","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"city":"Turku","zip":"20521","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"city":"Vaasa","zip":"65130","country":"Finland","geoPoint":{"lat":63.096,"lon":21.61577}},{"city":"Arras","zip":"62000","country":"France","geoPoint":{"lat":50.29301,"lon":2.78186}},{"city":"Lille Cedex","zip":"59037","country":"France","geoPoint":{"lat":50.63297,"lon":3.05858}},{"city":"Paris cedex 13","zip":"75013","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75012","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75018","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Pessac","zip":"33604","country":"France","geoPoint":{"lat":44.81011,"lon":-0.64129}},{"city":"TOULOUSE cedex","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"city":"Tours","zip":"37044","country":"France","geoPoint":{"lat":47.38333,"lon":0.68333}},{"city":"Vandoeuvre-les-nancy","zip":"54500","country":"France","geoPoint":{"lat":48.65,"lon":6.18333}},{"city":"Freiburg","state":"Baden-Württemberg","zip":"79106","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"city":"Nürnberg","state":"Bayern","zip":"90471","country":"Germany","geoPoint":{"lat":49.45421,"lon":11.07752}},{"city":"Frankfurt","state":"Hessen","zip":"60596","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"city":"Bad Oeynhausen","state":"Nordrhein-Westfalen","zip":"32545","country":"Germany","geoPoint":{"lat":52.20699,"lon":8.80365}},{"city":"Essen","state":"Nordrhein-Westfalen","zip":"45147","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"city":"Mönchengladbach","state":"Nordrhein-Westfalen","zip":"41063","country":"Germany","geoPoint":{"lat":51.18539,"lon":6.44172}},{"city":"Mainz","state":"Rheinland-Pfalz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98419,"lon":8.2791}},{"city":"Dresden","state":"Sachsen","zip":"01067","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"city":"Leipzig","state":"Sachsen","zip":"04289","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"city":"Berlin","zip":"13353","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"city":"Alexandroupolis","zip":"68100","country":"Greece","geoPoint":{"lat":40.84995,"lon":25.87644}},{"city":"Attica / Athens","zip":"11526","country":"Greece"},{"city":"Heraklion","zip":"711 10","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"city":"Thessaloniki","zip":"54642","country":"Greece","geoPoint":{"lat":40.64361,"lon":22.93086}},{"city":"Acquaviva delle Fonti","state":"Bari","zip":"70021","country":"Italy","geoPoint":{"lat":40.89704,"lon":16.8433}},{"city":"San Fermo della Battaglia","state":"Como","zip":"22020","country":"Italy","geoPoint":{"lat":45.80868,"lon":9.04744}},{"city":"San Donato Milanese","state":"Milano","zip":"20097","country":"Italy","geoPoint":{"lat":45.41047,"lon":9.26838}},{"city":"Mestre","state":"Venezia","zip":"30174","country":"Italy","geoPoint":{"lat":45.49167,"lon":12.24538}},{"city":"Ancona","zip":"60126","country":"Italy","geoPoint":{"lat":43.5942,"lon":13.50337}},{"city":"Catania","zip":"95126","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Roma","zip":"00169","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Torino","zip":"10126","country":"Italy","geoPoint":{"lat":45.07049,"lon":7.68682}},{"city":"Arnhem","zip":"6815 AD","country":"Netherlands","geoPoint":{"lat":51.98,"lon":5.91111}},{"city":"Haarlem","zip":"2035 RC","country":"Netherlands","geoPoint":{"lat":52.38084,"lon":4.63683}},{"city":"Heerlen","zip":"6419 PC","country":"Netherlands","geoPoint":{"lat":50.88365,"lon":5.98154}},{"city":"Leeuwarden","zip":"8934 AD","country":"Netherlands","geoPoint":{"lat":53.20139,"lon":5.80859}},{"city":"Maastricht","zip":"6229 HX","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"city":"Martinho do Bispo","state":"Coimbra","zip":"3041-801","country":"Portugal"},{"city":"Carnaxide","state":"Lisboa","zip":"2795-53","country":"Portugal","geoPoint":{"lat":38.72706,"lon":-9.24671}},{"city":"Almada","zip":"2801-951","country":"Portugal","geoPoint":{"lat":38.67902,"lon":-9.1569}},{"city":"Faro","zip":"8000-386","country":"Portugal","geoPoint":{"lat":37.01937,"lon":-7.93223}},{"city":"Lisboa","zip":"1169-024","country":"Portugal","geoPoint":{"lat":38.71667,"lon":-9.13333}},{"city":"Vila Nova de Gaia","zip":"4434-502","country":"Portugal","geoPoint":{"lat":41.13363,"lon":-8.61742}},{"city":"Singapore","zip":"119228","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Singapore","zip":"168752","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Singapore","zip":"308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Singapore","zip":"768828","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Alberton","state":"Gauteng","zip":"1449","country":"South Africa","geoPoint":{"lat":-26.26786,"lon":28.12225}},{"city":"Soweto","state":"Gauteng","zip":"2013","country":"South Africa","geoPoint":{"lat":-26.26781,"lon":27.85849}},{"city":"Cape Town","state":"Western Cape","zip":"7450","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"city":"Cape Town","state":"Western Cape","zip":"7505","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"city":"Kuils River","state":"Western Cape","zip":"7580","country":"South Africa","geoPoint":{"lat":-33.94208,"lon":18.70663}},{"city":"Somerset West","state":"Western Cape","zip":"7130","country":"South Africa","geoPoint":{"lat":-34.08401,"lon":18.82113}},{"city":"Worcester","state":"Western Cape","zip":"6850","country":"South Africa","geoPoint":{"lat":-33.64651,"lon":19.44852}},{"city":"Bloemfontein","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"city":"Majadahonda","state":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Granada","zip":"18012","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}},{"city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"city":"Chesterfield","state":"Derbyshire","zip":"S44 5BL","country":"United Kingdom","geoPoint":{"lat":53.25,"lon":-1.41667}},{"city":"Bournemouth","state":"Dorset","zip":"BH7 7DW","country":"United Kingdom","geoPoint":{"lat":50.72048,"lon":-1.8795}},{"city":"Welwyn Garden City","state":"Hertfordshire","zip":"AL7 4HQ","country":"United Kingdom","geoPoint":{"lat":51.80174,"lon":-0.20691}},{"city":"Leicester","state":"Leicestershire","zip":"LE3 9QP","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"city":"Nottingham","state":"Nottinghamshire","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"city":"Cliftonville","zip":"NN1 5BD","country":"United Kingdom","geoPoint":{"lat":51.38871,"lon":1.40505}},{"city":"London","zip":"SW17 0RE","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"city":"Portsmouth","zip":"PO6 3LY","country":"United Kingdom","geoPoint":{"lat":50.79899,"lon":-1.09125}}]},"referencesModule":{"references":[{"pmid":"25182247","type":"BACKGROUND","citation":"Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2."},{"pmid":"24944325","type":"BACKGROUND","citation":"Hai Z, Guangrui S. Cardiac paraganglioma. Eur Heart J. 2018 Jun 14;39(23):2219. doi: 10.1093/eurheartj/ehu241. No abstract available."}],"seeAlsoLinks":[{"label":"Click here to find information about studies related to Bayer Healthcare products conducted in Europe","url":"http://www.clinicaltrialsregister.eu/"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Overall, 1584 subjects were screened and 80 subjects did not complete or pass screening. 1504 subjects were randomized; 1002 were assigned to rivaroxaban and 502 to vitamin K antagonist (VKA).","recruitmentDetails":"The study was conducted at 141 centers (involving 144 investigators) in Europe, South Africa, North America, and Asia Pacific.","groups":[{"id":"FG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"FG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"periods":[{"title":"Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1002"},{"groupId":"FG001","numSubjects":"502"}]},{"type":"Subjects Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"988"},{"groupId":"FG001","numSubjects":"499"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"846"},{"groupId":"FG001","numSubjects":"400"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"102"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Efficacy outcome reached","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"Non-compliance with study drug","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Switching to other therapy","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Logistical difficulties","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Treatment failure","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"36"}]}]},{"title":"30-day Safety Follow-up Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"982"},{"groupId":"FG001","numSubjects":"487"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"924"},{"groupId":"FG001","numSubjects":"446"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"41"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Non-compliance with study drug","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"Logistical difficulties","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"BG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1002"},{"groupId":"BG001","value":"502"},{"groupId":"BG002","value":"1504"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.9","spread":"10.6"},{"groupId":"BG001","value":"64.7","spread":"10.5"},{"groupId":"BG002","value":"64.9","spread":"10.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"275"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"410"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"727"},{"groupId":"BG001","value":"367"},{"groupId":"BG002","value":"1094"}]}]}]},{"title":"CHADS 2 score","description":"Predicts clinical risk of stroke and thromboembolism in atrial fibrillation incorporating these risk factors: Congestive heart failure, Hypertension, Age \\[greater than or equal to (\\>=)75 years\\], Diabetes mellitus, Stroke/transient ischemic attack. Total score ranged from 0 to 6, with \"0\"= low risk, \"1\"= moderate risk and \"\\>=2\"= high risk.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1.3","spread":"1.1"},{"groupId":"BG001","value":"1.4","spread":"1.1"},{"groupId":"BG002","value":"1.4","spread":"1.1"}]}]}]},{"title":"CHA 2 DS 2 VASc score","description":"Predicts clinical risk of stroke and thromboembolism in atrial fibrillation incorporating these risk factors: Congestive heart failure/left ventricular dysfunction, Hypertension, Age \\>= 75 years, Diabetes mellitus, Stroke/transient ischemic attack/thromboembolism, Vascular disease (prior myocardial infarction, peripheral artery disease, or aortic plaque), Age 65 - 74 years, Sex category (i.e., female). Total score ranged from 0 to 8, with \"0\" (or 1 if female only)= Low risk ; \"1\" (except for female gender alone)= moderate risk and \"\\>=2\"=high risk.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2.3","spread":"1.6"},{"groupId":"BG001","value":"2.3","spread":"1.6"},{"groupId":"BG002","value":"2.3","spread":"1.6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death","description":"Stroke, TIA, Non-CNS Embolism, MI and cardiovascular death were adjudicated and confirmed by Clinical Endpoints Committee (CEC). Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. Cardiovascular death included death in subjects with non-valvular atrial fibrillation (AF). Number of subjects with composite events were reported.","populationDescription":"The primary population for the efficacy analysis was the modified intention-to-treat (mITT) population. mITT population included all the randomized subjects in whom a left atrial/left atrial appendage (LA/LAA) thrombus was not diagnosed during a transesophageal echocardiogram (TEE) performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no statistical test performed","paramType":"Risk Ratio (RR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.15","ciUpperLimit":"1.73","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.51% (0.20% - 1.17%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 1.02% (0.40% - 2.34%)."}]},{"type":"PRIMARY","title":"Number of Participants With Major Bleedings as Per Central Adjudication","description":"Bleeding events were adjudicated and confirmed by CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the International Society on Thrombosis and Hemostasis (ISTH) criteria. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Number of subjects with confirmed adjudicated bleeding events occurring in greater than (\\>)1 total subjects were reported.","populationDescription":"The safety profile was analyzed using the safety analysis set (SAF) population. SAF population included all randomized subjects who received at least 1 dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization up to the date of the last dose of study drug + 2 days","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"988"},{"groupId":"OG001","value":"499"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no test performed","paramType":"Risk Ratio (RR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.21","ciUpperLimit":"2.67","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.61% (0.26% - 1.27%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 0.80% (0.27% - 2.00%)."}]},{"type":"SECONDARY","title":"Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms","description":"Stroke and Non-CNS Embolism were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with composite events were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no statistical test performed","paramType":"Risk Ratio (RR)","paramValue":"0.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"2.00","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.20% (0.04% - 0.71%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 0.61% (0.17% - 1.72%)."}]},{"type":"SECONDARY","title":"Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality","description":"Stroke, TIA, Non- CNS systemic embolism, MI and all-cause mortality were adjudicated and confirmed by CEC. Stroke included hemorrhagic and ischemic infarction. TIA including information if with or without matching lesion. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). MI was assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. All-cause mortality included vascular death and non-vascular death. Number of subjects with composite events were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no statistical test performed","paramType":"Risk Ratio (RR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.16","ciUpperLimit":"1.55","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.61% (0.27% - 1.29%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 1.22% (0.53% - 2.51%)."}]},{"type":"SECONDARY","title":"Number of Participants With Strokes","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available). Number of subjects with strokes were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Transient Ischemic Attacks","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Number of subjects with TIA were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Non-central Nervous System Systemic Embolisms","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Non CNS systemic embolism included emboli in peripheral arterial of the upper and lower extremities, ocular and retinal (pulmonary embolism and MI were excluded from the category). Number of subjects with non-CNS embolism were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Myocardial Infarctions","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. MI was assessed based onmeither cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for \\>= 2 leads, or autopsy confirmation. Number of subjects with MI were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cardiovascular Deaths","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia). Number of subjects with cardiovascular deaths were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no statistical test performed","paramType":"Risk Ratio (RR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.18","ciUpperLimit":"5.47","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.41% (0.14% - 1.02%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 0.41% (0.07% - 1.41%)."}]},{"type":"SECONDARY","title":"Number of Participants With All-cause Mortality","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. All-cause mortality included vascular death and non-vascular death. Number of subjects with all-cause mortality were reported.","populationDescription":"The primary population for the efficacy analysis was the mITT population. mITT population included all the randomized subjects in whom a LA/LAA thrombus was not diagnosed during a TEE performed before the first planned cardioversion in the study.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization to the date of last dose of study drug +2 days for subjects who completed planned treatment or the earlier date [last planned dose, follow-up visit at the end of 30-day follow-up period] for subjects who prematurely stopped treatment","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"978"},{"groupId":"OG001","value":"492"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Descriptive comparison of crude estimates of the cumulative incidence and estimation of risk ratio, all with 95% confidence intervals","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","statisticalMethod":"no statistical test performed","paramType":"Risk Ratio (RR)","paramValue":"0.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.20","ciUpperLimit":"3.49","estimateComment":"Crude estimate of the cumulative incidence for rivaroxaban (Xarelto, BAY59-7939): 0.51% (0.20% - 1.17%). Crude estimate of the cumulative incidence for Vitamin K antagonist (VKA): 0.61% (0.17% - 1.72%)."}]},{"type":"SECONDARY","title":"Number of Participants With Composite of Major and Non-major Bleeding Events","description":"All events were adjudicated and confirmed by a CEC blinded to treatment. The CEC categorized the bleeding events as major or non-major. The bleeding events were defined per the ISTH criteria. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. Number of subjects with clinically relevant major and non-major bleeding events were reported.","populationDescription":"The safety profile was analyzed using the SAF population. SAF population included all randomized subjects who received at least 1 dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"From randomization up to the date of the last dose of study drug + 2 days","groups":[{"id":"OG000","title":"Rivaroxaban (Xarelto, BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period."},{"id":"OG001","title":"Vitamin K Antagonist (VKA)","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"988"},{"groupId":"OG001","value":"499"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"14"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"From first administration of study drug to date of last study drug + 2 days","eventGroups":[{"id":"EG000","title":"Rivaroxaban (Xarelto; BAY59-7939)","description":"Subjects randomized to treatment with rivaroxaban received rivaroxaban 20 milligram (mg) orally once daily. Subjects with moderate renal impairment \\[i.e., Creatinine clearance (CrCl) of 30 to 49 milliliter per minute (mL/min), inclusive\\] at screening received the adjusted dose of 15 mg once daily. The duration of the treatment period for a given subject depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, the cardioversion procedure was performed within 1-5 days after randomization. Rivaroxaban was given for 1-5 days before planned direct cardioversion and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received rivaroxaban for 21 (+4) to 56 (+4) days prior to cardioversion and for 42 days thereafter. The investigator assessed whether or not long-term anticoagulation was warranted and treated the subject according to standard of care. Then subjects entered 30-day follow-up period.","seriousNumAffected":93,"seriousNumAtRisk":988,"otherNumAffected":272,"otherNumAtRisk":988},{"id":"EG001","title":"Vitamin K Antagonist","description":"Subjects assigned to treatment with VKA received VKA orally once daily titrated to a target INR of 2.5 (range 2.0-3.0, inclusive). The specific VKA was given by the investigator based on local standard of practice. For all subjects randomized to receive VKA, the investigator assessed if a parenteral anticoagulant drug, particularly before cardioversion, was needed as bridging therapy with VKA as standard of care (until target INR was achieved). The duration depended on the cardioversion strategy. For subjects in the Direct Cardioversion Strategy, cardioversion was performed within 1-5 days after randomization. VKA was given for 1-5 days before it and for 42 days thereafter. Subjects in the Delayed Cardioversion Strategy received VKA for 21 (+4) to 56 (+4) days before cardioversion and for 42 days thereafter. The investigator assessed if long-term anticoagulation was warranted and treated the subject according to standard of care or not. Then subjects entered 30-day follow-up period.","seriousNumAffected":38,"seriousNumAtRisk":499,"otherNumAffected":126,"otherNumAtRisk":499}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":988},{"groupId":"EG001","numAffected":4,"numAtRisk":499}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Atrial tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Bradyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Cardiac failure chronic","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Intracardiac thrombus","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Mitral valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Rhythm idioventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Sick sinus syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Tachycardia induced cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Blindness transient","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Medical device site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Pseudomembranous colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Wound haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Arteriogram coronary","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Electrocardiogram PR prolongation","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Electrocardiogram T wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Liver function test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Arthritis reactive","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Bladder neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Thalamus haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":2,"numAtRisk":499}]},{"term":"Urogenital haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Pulmonary alveolar haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Bladder catheterisation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Cardiac ablation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Implantable defibrillator insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Plastic surgery","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Shoulder arthroplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":0,"numAtRisk":499}]}],"otherEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":988},{"groupId":"EG001","numAffected":7,"numAtRisk":499}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":988},{"groupId":"EG001","numAffected":6,"numAtRisk":499}]},{"term":"Atrioventricular block first degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":988},{"groupId":"EG001","numAffected":25,"numAtRisk":499}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":988},{"groupId":"EG001","numAffected":13,"numAtRisk":499}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":988},{"groupId":"EG001","numAffected":12,"numAtRisk":499}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":988},{"groupId":"EG001","numAffected":1,"numAtRisk":499}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":988},{"groupId":"EG001","numAffected":9,"numAtRisk":499}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":988},{"groupId":"EG001","numAffected":9,"numAtRisk":499}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":988},{"groupId":"EG001","numAffected":9,"numAtRisk":499}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":988},{"groupId":"EG001","numAffected":7,"numAtRisk":499}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":988},{"groupId":"EG001","numAffected":3,"numAtRisk":499}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":988},{"groupId":"EG001","numAffected":12,"numAtRisk":499}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":988},{"groupId":"EG001","numAffected":9,"numAtRisk":499}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":988},{"groupId":"EG001","numAffected":5,"numAtRisk":499}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (16.1)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":988},{"groupId":"EG001","numAffected":4,"numAtRisk":499}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Consultant agrees not to publish or cause to be published any works of authorship relating to the Project rendered pursuant to this Agreement without first notifying Bayer in writing and obtaining Bayer's written consent. Bayer will respond to such notification within sixty (60) days of receipt.Bayer reserves the right to insist on the removal of all or any of its Confidential Information from any such work prior to publication"},"pointOfContact":{"title":"Bayer HealthCare AG","organization":"Bayer HealthCare AG","email":"clinical-trials-contact@bayerhealthcare.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M16372","name":"Thromboembolism","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M5485","name":"Ischemic Attack, Transient","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M17292","name":"Warfarin","relevance":"LOW"},{"id":"M1271","name":"Acenocoumarol","relevance":"LOW"},{"id":"M13239","name":"Phenprocoumon","relevance":"LOW"},{"id":"M230212","name":"Fluindione","relevance":"LOW"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Vi","name":"Vitamins"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}